Skip to content
Prelude Therapeutics logo

Prelude Therapeutics (PRLD) Q1 2024 Earnings

PRLD·Reported May 7, 2024·Before market open

Diluted EPS came in at $-0.42, beat the $-0.47 consensus by $0.05.

Diluted EPS
$-0.42beat by $0.05
Consensus: $-0.47
SEC

SEC Filings

Earnings release8-K not filed yet

Financial Snapshot

Trailing eight quarters through Q1 2024

Q1 2024 Earnings FAQ

Common questions about Prelude Therapeutics's Q1 2024 earnings report.

Prelude Therapeutics (PRLD) reported Q1 2024 earnings on May 7, 2024 before market open.

Prelude Therapeutics reported diluted EPS of $-0.42 for Q1 2024.

EPS beat the consensus estimate of $-0.47 by $0.05.

You can read the 10-Q periodic report (0000950170-24-053940) directly on SEC EDGAR. The filing index links above go to sec.gov.